Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005761 · ClinicalTrials.gov registry record
Blood Factors and Diabetic Retinopathy
A clinical trial, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- 173
- Enrollment target
NCT00005761: Completed study, sponsored by National Eye Institute (NEI).
NCT00005761 is a clinical trial that has completed, run by National Eye Institute (NEI). The registered enrollment target is 173 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005761 has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- 173 participants
- Enrollment target
Study Summary
This study will determine whether certain factors in the blood are associated with the severity of diabetic retinopathy. Patients age 10 years and older with diabetes mellitus and diabetic retinopathy may be eligible for this study. Those enrolled will represent a range of diabetic retinopathy from minimal to severe. Participants will undergo the following procedures: * medical history * thorough eye examination * photographs of the eye * blood tests to measure blood lipids (cholesterol and triglycerides) and serum creatinine (for kidney function) * blood tests to measure levels of blood factors (cell adhesion molecules, chemokines and vascular endothelial growth factor) that may be related to the progression of diabetic retinopathy * blood pressure measurement * urinalysis This study may lead to a better understanding of how diabetic retinopathy develops and progresses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2000-05-23 |
| Est. Completion | 2010-12-07 |
What the finished NCT00005761 record still lists
NCT00005761 is an observational study that tracks outcomes without assigning an intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00005761 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005761 about?
NCT00005761 is a clinical study titled "Blood Factors and Diabetic Retinopathy". This study will determine whether certain factors in the blood are associated with the severity of diabetic retinopathy. Patients age 10 years and older with diabetes mellitus and diabetic retinopathy may be eligible for this study. Those enrolled will represent a range of diabetic retinopathy from...
What is the current status of trial NCT00005761?
This trial is currently completed. The enrollment target is 173 participants. The study started on 2000-05-23. Estimated completion is 2010-12-07.
Who is sponsoring clinical trial NCT00005761?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05568719 · 173 participants · Phase 3
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- NCT07070115 · 173 participants · NA
Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
- NCT07150832 · 173 participants · NA
Efficacy of the I-CARE Digital Health Intervention
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI